AdaptHealth Corp vs Atomera Incorporated — how do they compare? AdaptHealth Corp trades at $5.66 (market cap $759.10M), while Atomera Incorporated trades at $5.57 (market cap $209.56M). The key difference: AdaptHealth Corp is far larger — about 3.6× Atomera Incorporated's market cap, and Atomera Incorporated is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | ATOM | |
|---|---|---|
Market Cap | $759.10M | $209.56M |
Sector | Health | Technology |
52-Week High | $13.38 | $12.11 |
52-Week Low | $5.22 | $1.99 |
Enterprise Value | $2.78B | $172.37M |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth Corp. (AHCO) trades at $5.69, down 5.87% in the last 24 hours, reflecting negative sentiment after recent earnings misses and lowered guidance. The stock shows a bearish technical signal with support near $5, while fundamentals reveal revenue of $3.24 billion in 2025 but a net loss of $70.79 million, with profitability metrics like net margin at -6.82% indicating operational challenges. Recent news highlights multiple law firm investigations into potential securities fraud following disappointing Q2 2026 results.
The outlook for AHCO is cautious due to persistent earnings underperformance and rising costs from fixed-price contracts. While analyst consensus remains bullish with a $11.00 price target, significant risks include ongoing legal scrutiny, margin pressure, and execution uncertainties. Investors should weigh the high institutional buy ratings against fundamental weaknesses and recent negative developments.
ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.
Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.
Trailing returns across standard periods
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →